ClinicalTrials.gg
RecruitingNCT07334691Updated May 11, 2026

TARGET 2.0 Study: Safety and Performance of the Cardiovalve TR Replacement System

An interventional study of Cardiovalve TR valve replacement System in Tricuspid Regurgitation, sponsored by Cardiovalve Ltd.. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Cardiovalve Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 51 studies in Tricuspid Valve Insufficiency with a site in Germany — 24 open to participants now, 31 under way, none of them phase 3. Tricuspid Valve Insufficiency · Germany.

Planned enrollment
7th of 25
150 · median 60
Started
2026
with 2 others
No phase
23 of 51
7 open now
Primary completion
2028-06
later than 20 of 30 live
Registered
48th of 51
by date
Lead sponsor
2 of 51
Cardiovalve Ltd.

Among the 51 studies in Tricuspid Valve Insufficiency with a site in Germany, this one is the 7th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2026, is one of 23 with no phase, reaches primary completion later than 20 of the 30 other live ones, and was the 48th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

24 of the 51 studies in Tricuspid Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Tricuspid Valve Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

This investigation is a continuation for "TARGET" investigation and its purpose is to further demonstrate the efficiency and safety of the Cardiovalve system in the treatment of subjects with tricuspid regurgitation. The same subject population will be included, while applying the clinical and scientific knowledge accumulated in the TARGET investigation. This investigation will support the submission for obtaining marketing approval.

Read the detailed description

"TARGET 2.0": Safety and Performance of the Cardiovalve Tricuspid valve replacement system in the treatment of subjects with tricuspid regurgitation- investigation: Cardiovalve Tricuspid Valve Replacement system (hereinafter referred to as Cardiovalve TR system) The system has not been granted CE mark at this time The Cardiovalve implant consists of three bovine pericardium tissue leaflets, self-expanding dual nitinol frame, and fabric. A total of 24 anchoring points affix the device to the native tricuspid annulus.

The Delivery System is intended to deliver the valve in the crimped position via the transfemoral venous approach. It comprises of a catheter assembly and handles. The handles knobs facilitate valve alignment and positioning in the native valve, and control the capsule expansion and release of the Cardiovalve implant.

The Cardiovalve TR Valve Replacement System is intended for reduction of tricuspid regurgitation (TR) in patients with symptomatic severe or greater secondary tricuspid regurgitation despite being treated with medical therapy for whom tricuspid valve replacement is deemed appropriate by a Heart Team. The system percutaneously delivers the Implant to the tricuspid valve via femoral vein access This investigation is a continuation for "TARGET" investigation and its purpose is to further demonstrate the efficiency and safety of the Cardiovalve system in the treatment of subjects with tricuspid regurgitation. The same subject population will be included, while applying the clinical and scientific knowledge accumulated in the TARGET investigation. This investigation will support the submission for obtaining marketing approval.

03

Conditions studied

  • Tricuspid Regurgitation
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is ≥ 18 and \<85 years
  2. Severe tricuspid regurgitation (TR) ≥3+ based upon echocardiography, as assessed by independent core laboratory using a 5-grade classification (mild (1), moderate (2), severe (3), massive (4), torrential (5)). Trace and no TR is considered 0)29
  3. Symptomatic, Class II-IV
  4. (LVEF) ≥ 30%
  5. Subject adequately treated based upon medical standards
  6. Subjects are at high risk for open heart surgery
  7. Subject provided written, before investigation enrollment
  8. Subject approved by the Subject Screening Committee

    Anatomical Inclusion Criteria (measured by CT)

  9. Right femoral vein diameter > 9mm
  10. Tricuspid valve diameter \< 55 mm
  11. RV length > 45 mm

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the investigation if fulfill any of the following criteria:

  1. Cardiac anatomy deemed not suitable for the Cardiovalve TR system as evaluated (by CT)
  2. Venous peripheral anatomy or any spinal anatomy that is unsuitable for Cardiovalve TR implant delivery (by CT)
  3. Primary tricuspid disease that may interfere with Cardiovalve implantation
  4. Severe right ventricular failure (by Echo core lab adjudication)
  5. Significant coronary artery disease requiring percutaneous or surgical intervention
  6. Severe systolic pulmonary arterial pressure, pASP > 2/3 systemic BP with PVR > 5 Wood units after vasodilator challenge
  7. Presence of any known life threatening non-cardiac disease that will limit the subject's to less than one year
  8. Cerebrovascular event (stroke, ) within the past 3 months
  9. Active endocarditis or history of mitral/tricuspid endocarditis within 3 months or infection requiring antibiotic within 2 weeks before index procedure
  10. Subject has significant other sided valvular heart disease which requires treatment (e.g. mitral regurgitation or stenosis, or aortic regurgitation or stenosis)
  11. Documented primary coagulopathy or disorder, including thrombocytopenia (absolute platelet count \<90k)
  12. Documented evidence of significant renal dysfunction (\<30 ml/min/1.73m2) or any form of dialysis at time of screening within 30 days
  13. Untreatable or to any of the following: all antiplatelets, all anticoagulants, nitinol alloys (nickel and titanium), bovine tissue, glutaraldehyde, contrast media, or Polyethylene Glycol (PEG)
  14. Subjects unsuitable for implantation due to thrombosis of the lower venous system or presence of a vena cava filter
  15. Evidence of an acute myocardial infarction (AMI) ≤ 1 month (30 days)
  16. Liver cirrhosis > Class A
  17. Psychiatric or behavioral disease including known alcohol or drug abuser that is likely to impair compliance with protocol
  18. Pregnant, lactating or planning pregnancy within next 12 months
  19. Requirement for antibiotic treatment within the last 48 hours
  20. Surgical or interventional procedure planned within 30 days prior to index procedure
  21. heart failure requiring advanced intervention (i.e. left ventricular assist device, transplantation) or UNOS Status 1 heart transplant or prior orthotropic heart transplantation.
  22. Prior Tricuspid valve surgery or transcatheter tricuspid valve procedure that may interfere with the Cardiovalve device. Valve in a valve procedure is excluded.
  23. Modified Rankin Scale > 4 disability
  24. Implant or revision of any rhythm management device (CRT or CRT-D) or implantable cardioverter-defibrillator within 30 days prior to index procedure
  25. Acutely decompensated heart failure (i.e. hemodynamically unstable or requiring IV inotrope) at the time of screening
  26. Severe or continuous use of home oxygen
  27. \< 9 g/dL at screening
  28. The subject has contraindication against a transesophageal echo (TEE) during the procedure that cannot be replaced by other imaging.
  29. Currently participating in an drug or another device investigation which has not reached its primary endpoint
  30. Subjects with >2 leads or with any lead that may interfere with Cardiovalve procedure or device
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Cardiovalve TR valve replacement System

    The Cardiovalve system includes a valve and delivery system, designed for replacement of the tricuspid valve through a transcatheter.

    Device: Cardiovalve TR valve replacement System

Interventions

  • DeviceCardiovalve TR valve replacement System

    Cardiovalve Tricuspid Valve Replacement system

06

What researchers measure

Primary outcomes

  1. Freedom from device or procedure-related adverse events

    Freedom from device or procedure-related adverse events

    Time frame: 30 days

  2. Reduction in TR grade

    Reduction in TR in comparison to baseline

    Time frame: 30 days

Secondary outcomes

  1. Six minute walk test

    Change in Six minute walk distance from Baseline

    Time frame: 30 days, 6 months, 12 months, annual for five years

  2. KCCQ

    Change in health status from Baseline

    Time frame: 30 days, 6 months, 12 months, annual for five years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2028, 29 months after the start.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 29 months is below that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2025
First posted
Jan 12, 2026
StartActual
Jan 20, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Sep 2033
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07334691
Lead sponsor
Cardiovalve Ltd.
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Jan 20, 2026
Primary completion
Jun 2028 (estimated)
Completion
Sep 2033 (estimated)
Last update
May 11, 2026

Study contacts

Dana Raveh Arbel
Contact
danar@cardiovalve.com
0528591891
Georg Nickenig
principal investigator · Bonn Clinic

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion